Varicella zoster immune globulin Disease Interactions
There is 1 disease interaction with varicella zoster immune globulin.
Varicella zoster immune globulin (applies to varicella zoster immune globulin) thrombotic events
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Coagulation Defect, Heart Disease, History - Thrombotic/Thromboembolic Disorder, Thrombocytopenia
Thrombotic events may occur during or after treatment with varicella zoster immune globulin. At-risk patients include those with history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known/suspected hyperviscosity. Baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity (including patients with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols [triglycerides], or monoclonal gammopathies). Varicella zoster immune globulin should be administered IM only. In patients with severe thrombocytopenia or any coagulation disorder that would contraindicate IM injections, varicella zoster immune globulin should be administered only if the expected benefits outweigh the potential risks.
References (1)
- (2022) "Product Information. Varizig (varicella zoster immune globulin)." Kamada Inc.
Switch to consumer interaction data
Varicella zoster immune globulin drug interactions
There are 22 drug interactions with varicella zoster immune globulin.
More about varicella zoster immune globulin
- varicella zoster immune globulin consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: immune globulins
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.